Search Bar & Filters
Found 687 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the long-term outcomes of stopping endoscopic surveillance in patients with low-risk non-dysplastic Barrett esophagus NDBE. Traditionally, these patients were monitored every 3 to 5 years to reduce death from esophageal adenocarcinoma EAC, but recent guidelines suggest stopping surveillance for low-risk individuals due to lack of evidence for survival benefit and cost-effectiveness. The study seeks to determine if discontinuing surveillance leads to an increase in clinically significant EAC cases. Participants in the Netherlands with low-risk NDBEcharacterized by Barretts esophagus less than 5 cm, no history of dysplasia, and no family history of EACwill have their endoscopic surveillance stopped according to new guidelines. They will be followed as part of a prospective observational cohort without additional interventions. Data will be gathered from medical records and national registries, including pathology and cancer databases, to track outcomes. Participants will provide informed consent for inclusion in the registry but will not undergo extra procedures or active treatments. Researchers will annually review data for the incidence of clinically apparent EAC, defined by cancer-related death or cancer requiring advanced treatment. The study will follow participants for at least 10 years, ensuring privacy protections and minimal burden while monitoring the effects of this new surveillance approach.
Actively Recruiting
Young adults aged 18 to 25 who experience frequent thoughts about killing themselves are the focus of this study, which evaluates the cost-effectiveness of Attachment Based Family Therapy ABFT compared to Treatment As Usual TAU. Suicide is a leading cause of death among young adults, and current treatments have limited success. This trial aims to determine if involving family through ABFT can better reduce suicidality and improve outcomes, informing clinical guidelines and care practices in Belgium and the Netherlands. Participants are randomly assigned to one of two groups the experimental group receives ABFT as an add-on to TAU, which includes treatments like antidepressants, CBT, or DBT, with weekly ABFT sessions lasting about 16 weeks. The control group receives TAU alone, allowing up to four sessions of systemic family therapy. ABFT focuses on strengthening parent-child attachment bonds to provide a supportive base for young adults, involving parents or caregivers actively in therapy. Throughout the study, suicidality is measured at baseline, immediately after intervention, and at follow-ups 3, 6, and 12 months post-intervention using tools like the Suicidal Ideation Questionnaire Junior. Researchers also assess depressive symptoms, family functioning, attachment, quality of life, and healthcare costs. The trial includes 138 participants across multiple sites, with double-blind randomized allocation. Safety, adherence, and cost-effectiveness are closely monitored during and after the treatment period.
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Researchers are comparing 3D-printed hand orthoses with conventional custom-made orthoses in people with chronic hand conditions, such as neurological, musculoskeletal, or neuromuscular disorders. This study aims to determine if 3D-printed orthoses are not worse than conventional ones in improving daily hand function, pain, quality of life, and overall functional status. It also evaluates patient satisfaction and cost-effectiveness of these two types of orthoses. Participants will be randomly assigned to receive either a 3D-printed hand orthosis or a conventional hand orthosis made from a plaster cast. Both types are designed for permanent use to improve performance in daily activities involving the hand. The study measures production time and costs, as well as user experiences with the orthoses and their development by orthotists. During the study, participants will be assessed at screening, baseline 2 weeks after screening, and at 1, 4, 8, and 12 months after receiving the orthosis. Assessments include measuring daily activity performance, hand function, pain, quality of life, functional status, and satisfaction with the orthosis using various questionnaires. Production details and cost data will also be collected. The total participation duration lasts up to 12 months after orthosis delivery.
Actively Recruiting
Healthy Volunteer
3TR-ABC follows people with severe asthma from the day they start a biologic and keeps following them for three years. It is observational, meaning the study does not decide who gets which drug. Patients begin their biologic through normal clinical channels, according to whatever criteria apply in their country, and the study observes what happens next. The point is to work out why these expensive, highly targeted drugs transform life for some patients and do very little for others. The structure is a platform rather than a single trial. One shared core design sits underneath, and individual studies focused on specific biologics run on top of it, each free to add its own extra measurements while keeping the visit schedule and sampling aligned so results can be pooled. Only patients who have never had a biologic before are enrolled. They are assessed thoroughly at the start, then seen again at 4 weeks, 16 weeks, 52 weeks, and at the 2 and 3 year marks, with additional sampling whenever an exacerbation happens. Some sites collect a core package of samples, others an expanded one. Behind it all is the 3TR Consortium, a collaboration spanning 15 European countries and 69 partners, working across seven immune-driven diseases including asthma, COPD, Crohns disease, ulcerative colitis, multiple sclerosis, lupus, and rheumatoid arthritis. It is the largest immunology project the Innovative Medicines Initiative has funded. The asthma work sits in what the consortium calls work package 8, and its guiding questions are blunt ones what separates a good responder from a non-responder, and can severe asthma actually be pushed into remission rather than merely managed. Participants are sorted after the fact into three groups based on how they did remission, clinical response, and non-response. The blood, tissue, and breath samples collected before anyone started treatment are then compared across those groups, along with how each groups immune activity shifted over time. Healthy volunteers and people with mild or moderate controlled asthma go through the same baseline visit and serve as reference points, giving the researchers a sense of what these markers look like outside of severe disease. Samples feed into multi-omic analysis, which means examining genes, proteins, metabolites and more from the same person to map the biological pathways involved. The main target is a set of baseline markers that predict remission at one year. Remission here has a specific definition an ACQ-5 score below 1.5, lung function after bronchodilator either at or above 80% of predicted or improved by more than 10%, no exacerbations, and no maintenance steroid use across the previous twelve months. The same question is asked again at three years, alongside how marker profiles shift between those who reach remission and those who dont, how each individual response measure behaves, and how physician and patient ratings of treatment benefit compare with the consortiums own composite response measure. Exploratory work applies network and cluster analysis, discriminant methods such as PLSDA, daily FENO readings, and analysis of host and microbiome interaction to hunt for biomarker signatures nobody has identified yet. One cohort within the platform, AIR-BIO-OCT, focuses on patients taking benralizumab and goes a step further into the airway wall itself. Biologics are currently matched to patients through phenotyping that leans on clinical features, oral steroid use, and eosinophil counts in blood, sputum, or lavage fluid. What remains unclear is whether these drugs change airway remodeling, the structural thickening involving smooth muscle and extracellular matrix that tracks with how severe and how persistent the disease becomes. This substudy pairs exhaled breath analysis, using both GC-MS and electronic nose technology to read volatile organic compounds, with omics and with optical coherence tomography imaging, including a polarization-sensitive form of OCT. Endobronchial biopsies alongside the imaging are used to establish whether smooth muscle and matrix actually decrease after six months to a year on benralizumab. The broader hope is a minimally invasive breath-based signature that could flag likely responders before treatment ever starts.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a new radioactive tracer called 18FACI-19626 for its ability to detect pathological protein TDP-43 in the brain. This protein is involved in rare forms of dementia such as frontotemporal dementia FTD and amyotrophic lateral sclerosis ALS. The study also aims to assess the safety and tolerability of this tracer when injected into participants, including both healthy individuals and those with suspected TDP-43 accumulation. Participants will receive the 18FACI-19626 tracer intravenously followed by brain scans using positron emission tomography PET. The study includes up to 45 participants divided into groups including healthy controls and those with TDP-43 proteinopathies or related neurodegenerative diseases. Some participants may undergo a second PET scan within one month to evaluate the reliability of the tracers measurements. During the study, participants will attend two to three visits over about three months. These visits include eligibility screening with physical and neurological exams, questionnaires, blood and urine tests, ECG, and sometimes MRI. After the PET scan, blood samples will be collected, and a follow-up phone call will check for any side effects. Researchers will measure brain uptake of the tracer, monitor vital signs, and track any adverse events to assess safety and imaging accuracy.
Actively Recruiting
Carcinoma of unknown primary origin CUP is a group of cancers where metastatic disease is present but the original tumor cannot be found despite extensive tests. This condition limits treatment options since therapies often target known primary tumors. Researchers are evaluating whether a new imaging test called 18FF-fluoro fibroblast activation protein inhibitor F-FAPI PET-CT can detect the primary tumor in patients diagnosed with CUP after standard diagnostic scans including FDG PET-CT. This multi-center, prospective clinical study involves 50 adult patients with CUP to better understand the usefulness of this new scan method. Each participant will undergo a single 18FF-FAPI PET-CT scan at one of the six study centers. Images from this scan will be centrally reviewed and shared with the treating doctor, who may recommend further tests or treatments based on the findings. After six months, results from the F-FAPI PET-CT will be compared with clinical, radiological, and pathological follow-up data. A multidisciplinary panel will then review all information to decide how valuable the 18FF-FAPI PET-CT is for identifying the primary tumor in CUP patients. Participants will be involved in one main scanning visit and followed for six months through routine clinical assessments. The study team will monitor detection of the primary tumor using the new scan as the main outcome, and also assess the tests accuracy measures like sensitivity and specificity. Participation requires being able to undergo the scan and complete follow-up, with the entire process lasting about two years for outcome measurement. This study is sponsored by Erasmus Medical Center.
Actively Recruiting
Researchers are studying a new type of scan called FAPI-PETCT to see how well it detects metastases in patients with advanced gastric cancer. The study aims to find out if this scan can better identify cancer spread, leading to changes in treatment plans such as avoiding unnecessary surgeries or shifting to comfort-focused care. It also evaluates whether the scan causes less burden for patients compared to current methods. Participants will receive the standard care for gastric cancer and undergo one additional FAPI-PETCT scan, where a small amount of 18F-FAPI-74 is given intravenously about 60 minutes before a PETCT scan lasting around 20 minutes. The results from this scan will help doctors decide on further tests or surgery needed. The study monitors changes in diagnosis and treatment decisions based on the scan. During the study, participants will complete questionnaires taking about 4 hours total and spend approximately 2 hours for the extra scan. Researchers will measure outcomes such as changes in treatment intent, diagnostic work-up, scan accuracy, incidental findings, patient burden, quality of life, and safety over about one year. Follow-up includes quality of life assessments and cost evaluations at multiple time points after staging.
Actively Recruiting
Researchers are studying changes in the uptake of 18FF-AraG, a tracer that images activated T-cells, in patients with non-small cell lung cancer NSCLC undergoing anti-PD-1 immunotherapy. The goal is to better understand the tumor microenvironment and how it relates to immune cell activity, which may help improve patient selection for immunotherapy. The study focuses on advanced-stage NSCLC patients with specific tumor characteristics and high PD-L1 expression. Participants will undergo three 18FF-AraG PET scans during their anti-PD-1 treatment at the start baseline, at two weeks, and at six weeks. These scans are performed to track the accumulation of activated T-cells in tumor lesions and lymphoid organs over time. The study does not involve additional treatments but monitors changes using this imaging technique. During the study, participants will be monitored through these PET scans and assessments of tumor response to treatment at 12 weeks. Researchers will measure the relative change in tracer uptake and correlate it with tumor response and T-cell activation. Participants will be followed for up to 12 weeks to evaluate these outcomes. Safety and eligibility are carefully assessed, and participants provide informed consent before enrollment.
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.
1-10 of 687
1